Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Reverse conditioning can help achieve volume and well-conditioned hair for those with diffuse thinning. The user also mentioned using dutasteride.

The conversation discusses whether adding latanoprost to finasteride and minoxidil is more effective for hair loss than using finasteride and minoxidil alone. Users criticize the lack of comparison to the established combination of finasteride and minoxidil.

PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.

Topical dutasteride, particularly at 0.05%, shows greater hair density improvement than oral finasteride over 24 weeks, though hair thickness gains are similar. Some users report side effects with topical treatments, but others find them effective for maintaining hair without significant systemic absorption.

Topical dutasteride is more effective than oral finasteride for male pattern hair loss, with fewer side effects. Some prefer oral treatments for convenience, while others use topical solutions like minoxidil and dutasteride, sometimes with microneedling, for better results.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

User shared 9-month hair regrowth progress using a Fin/Min spray from HIMS, with additional microneedling. Other users praised the results and discussed the effectiveness of topical treatments.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.

Hair loss treatments advertised on Instagram are likely ineffective and considered scams. Effective treatments like Minoxidil and Finasteride don't need advertising due to high demand.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

Finding treatments for regrowth on the hairline which have not been successful so far, with suggestions of maintaining what they currently have and considering a hair transplant as an option.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

Creatine supplementation may increase DHT levels, potentially affecting hair loss. A study is examining this effect, with participants taking 5 grams of creatine daily for six months.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

Dermarolling has potential for hair regrowth and is being used alongside minoxidil and a rosemary oil/castor oil mix. Users discuss its effectiveness and the need for more research.

Some actors are believed to use treatments like finasteride, minoxidil, or hair transplants to maintain their hair, while others are thought to have naturally good genetics. Opinions vary on whether celebrities like Brad Pitt have natural hair or use enhancements.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.

Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.